KR102365198B1 - Facturing method of functional liquefied healthfoods using Gastroia elata Blume, Polygonum multiflorum Thunberg and mountain ginseng - Google Patents
Facturing method of functional liquefied healthfoods using Gastroia elata Blume, Polygonum multiflorum Thunberg and mountain ginseng Download PDFInfo
- Publication number
- KR102365198B1 KR102365198B1 KR1020190169219A KR20190169219A KR102365198B1 KR 102365198 B1 KR102365198 B1 KR 102365198B1 KR 1020190169219 A KR1020190169219 A KR 1020190169219A KR 20190169219 A KR20190169219 A KR 20190169219A KR 102365198 B1 KR102365198 B1 KR 102365198B1
- Authority
- KR
- South Korea
- Prior art keywords
- chunma
- fermented
- drying
- fermentation
- ginseng
- Prior art date
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 50
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 49
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 28
- 235000013402 health food Nutrition 0.000 title claims abstract description 12
- 241000208340 Araliaceae Species 0.000 title claims abstract description 7
- 241001289529 Fallopia multiflora Species 0.000 title description 4
- 239000003814 drug Substances 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000047 product Substances 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 230000008569 process Effects 0.000 claims abstract description 15
- 241000894006 Bacteria Species 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims abstract description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003231 vitamin Natural products 0.000 claims abstract description 12
- 239000011782 vitamin Substances 0.000 claims abstract description 12
- 235000013343 vitamin Nutrition 0.000 claims abstract description 12
- 229940088594 vitamin Drugs 0.000 claims abstract description 12
- 230000003321 amplification Effects 0.000 claims abstract description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 238000010025 steaming Methods 0.000 claims abstract description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 6
- 239000004310 lactic acid Substances 0.000 claims abstract description 6
- 239000011707 mineral Substances 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 235000021108 sauerkraut Nutrition 0.000 claims abstract description 5
- 238000004898 kneading Methods 0.000 claims abstract description 3
- 239000012263 liquid product Substances 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 15
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 13
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 13
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 241000186660 Lactobacillus Species 0.000 claims description 11
- 229940039696 lactobacillus Drugs 0.000 claims description 10
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 9
- 244000163122 Curcuma domestica Species 0.000 claims description 3
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 3
- 244000241838 Lycium barbarum Species 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 235000004347 Perilla Nutrition 0.000 claims description 3
- 244000124853 Perilla frutescens Species 0.000 claims description 3
- 235000003373 curcuma longa Nutrition 0.000 claims description 3
- 235000013976 turmeric Nutrition 0.000 claims description 3
- 235000015701 Artemisia arbuscula Nutrition 0.000 claims description 2
- 235000002657 Artemisia tridentata Nutrition 0.000 claims description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 2
- 240000006891 Artemisia vulgaris Species 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 235000007215 black sesame Nutrition 0.000 claims description 2
- 235000021329 brown rice Nutrition 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 12
- 235000013305 food Nutrition 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 238000010298 pulverizing process Methods 0.000 abstract description 4
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract description 3
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract description 3
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract description 3
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract description 3
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract description 3
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract description 3
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract description 3
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract description 3
- 240000000171 Crataegus monogyna Species 0.000 abstract description 3
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract description 3
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 239000010865 sewage Substances 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 235000019629 palatability Nutrition 0.000 abstract description 2
- 208000019553 vascular disease Diseases 0.000 abstract description 2
- 235000019621 digestibility Nutrition 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000012041 food component Nutrition 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 description 52
- 230000004151 fermentation Effects 0.000 description 52
- 240000004371 Panax ginseng Species 0.000 description 44
- 230000003078 antioxidant effect Effects 0.000 description 21
- 239000000284 extract Substances 0.000 description 21
- 235000013824 polyphenols Nutrition 0.000 description 18
- 230000002292 Radical scavenging effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 150000008442 polyphenolic compounds Chemical class 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 239000003963 antioxidant agent Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 9
- 239000000401 methanolic extract Substances 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 7
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 7
- 241000411851 herbal medicine Species 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 229930182494 ginsenoside Natural products 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 6
- -1 phenol compounds Chemical class 0.000 description 6
- 230000001766 physiological effect Effects 0.000 description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 5
- 150000002989 phenols Chemical class 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940124595 oriental medicine Drugs 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- ZENOXNGFMSCLLL-UHFFFAOYSA-N vanillyl alcohol Chemical compound COC1=CC(CO)=CC=C1O ZENOXNGFMSCLLL-UHFFFAOYSA-N 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 3
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 3
- 235000012141 vanillin Nutrition 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 2
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 2
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930193974 gastrodin Natural products 0.000 description 2
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000195967 Anthoceros Species 0.000 description 1
- 244000221226 Armillaria mellea Species 0.000 description 1
- 235000011569 Armillaria mellea Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 240000008100 Brassica rapa Species 0.000 description 1
- 235000011292 Brassica rapa Nutrition 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241000393548 Candidae Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 description 1
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- SKPPEIDJGJGRGK-UHFFFAOYSA-N Panacen Natural products CCC1=CC=CC2=C1C1OC(C=C=CBr)CC1O2 SKPPEIDJGJGRGK-UHFFFAOYSA-N 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- PXKLMJQFEQBVLD-UHFFFAOYSA-N bisphenol F Chemical compound C1=CC(O)=CC=C1CC1=CC=C(O)C=C1 PXKLMJQFEQBVLD-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 1
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003129 oil well Substances 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940124594 traditional oriental medicine Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000006499 vasodilator function Effects 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A23Y2220/00—
Abstract
본 발명은 천마, 하수오 및 산양삼을 이용한 기능성 액상 건강식품의 제조 방법에 관한 것으로서, 보다 상세하게는 1) 천마를 슬라이스 하고 찌고 말리는 증폭 과정을 반복한 후 건조시키는 단계; 2) 하수오를 찌고 말리는 증폭 과정을 반복하는 단계; 3) 상기 1) 천마와 2) 하수오를 혼합하고 상기 약재를 분말화하는 단계; 4) 상기 분말화된 약재를 생수로 반죽하고 당을 첨가한 후 유산균 발효균주로 발효시키는 단계; 및 5) 상기 발효물을 여과하고 농축하여 액상 제품을 제조하는 단계;를 포함하는 기능성 액상 건강식품의 제조 방법에 관한 것이다. 본 발명의 식품은 천마와 하수오의 우수한 영양 성분과 더불어 황국균과 같은 발효 균주에 의한 발효로 다양한 아미노산류, 비타민류 등의 성분들이 어우러져 영양가를 더욱 증가시키고 생체 신진대사를 촉진시키며, 천마와 하수오가 가지고 있는 특유의 강한 향과 맛을 순화시켜 이미, 이취가 없는 액상으로 제조되어 기호성이 크게 향상되고, 소화력이 우수하며 복용감도 훨씬 좋아지며, 순환기나 혈관 질환과 같은 각종 질병의 예방에 효과적이다.The present invention relates to a method for producing a functional liquid health food using Chunma, Hawthorn and wild ginseng, and more particularly, the steps of: 1) slicing Chunma, and repeating the amplification process of steaming and drying, followed by drying; 2) repeating the amplification process of steaming and drying the sewage; 3) mixing the 1) cheonma and 2) sauerkraut and pulverizing the medicine; 4) kneading the powdered medicinal material with mineral water, adding sugar, and fermenting it with a lactic acid bacteria fermenting strain; And 5) filtering and concentrating the fermented product to prepare a liquid product; relates to a method for producing a functional liquid health food comprising. The food of the present invention is fermented by fermented strains such as Hwang Guk-gyun as well as excellent nutritional components of Chunma and Sauerkraut, so that various amino acids and vitamins are harmonized to further increase the nutritional value and promote metabolism in the body. By purifying its unique strong scent and taste, it has already been prepared as a liquid without off-flavor, so the palatability is greatly improved, the digestibility is excellent and the dosage is much better, and it is effective in the prevention of various diseases such as circulatory and vascular diseases.
Description
본 발명은 천마, 하수오 및 산양삼을 이용한 기능성 액상 건강식품의 제조 방법에 관한 것이다.The present invention relates to a method for manufacturing a functional liquid health food using cheonma, saueri and wild ginseng.
천마(天麻, Gastroia elata Blume)는 난초과(Orchidaceae) 식물에 속하는 다년초로써 담자균류인 뽕나무버섯 속(Armillaria mellea) 균사와 공생하며 땅속의 괴경을 가지며, 한방에서의 천마는 고혈압, 두통, 마비, 신경성질환, 당뇨병, 간질, 어지럼증 등의 증상에 대하여 효능이 있는 것으로 알려져 있다(Lee, Y.B. 1990. Dictionary of oriental medicine. Sam moon dang. p. 814). 천마는 gastrodin, vanillyl alcohol, vanillin, benzaldehydes, p-hydroxybenzyl alcohol 등의 약리성분이 함유되어 있어 체내에서 생리활성을 가진 것으로 보고되었고(Taguchi et al., 1981, Chem. Pharm. Bull. 29:55-62), 생천마로부터 4,4-dihydroxy-diphenyl methane 등의 phenolic compounds의 존재를 확인하였다(Zhou et al., 1980, Acta botanica Yunnanica. 2:370-372). 또한, 들깨유를 기질로 한 천마추출물의 항산화력은 합성항산화제인 BHT 보다 높게 나타내었고 천마추출물의 농도가 증가할수록 항산화력도 증가하였음을 보고하였으며, 천마는 DPPH, FRAP 라디칼 소거능에서 높은 활성능이 있음을 보고하였다. 천마의 주요성분인 p-hydroxybenzyl alcohol과 vanillin은 DPPH, superoxide, hydroxyl 라디칼 소거능에서 강력한 항산화 효과가 있으며, in vitro, in vivo에서 항산화제로서 탁월한 효과가 있음을 보고하였다. 이와 같이 천마를 식품소재로 이용하기 위해 다각적인 연구가 요구되며, 최근에 천연물을 발효나 효소를 처리하여 다양한 생리활성 연구가 진행되고 있으나 천마는 아직까지 발효를 이용하여 생리활성을 규명한 연구는 부족한 실정이다.Gastroia elata Blume (天麻, Gastroia elata Blume) is a perennial plant belonging to the Orchidaceae family. It coexists with the basidiomycete, Armillaria mellea, and has tubers underground. , diabetes, epilepsy, is known to be effective against symptoms such as dizziness (Lee, YB 1990. Dictionary of oriental medicine. Sam moon dang. p. 814). Chunma contains pharmacological ingredients such as gastrodin, vanillyl alcohol, vanillin, benzaldehydes, and p-hydroxybenzyl alcohol, and has been reported to have physiological activity in the body (Taguchi et al., 1981, Chem. Pharm. Bull. 29:55- 62), confirmed the presence of phenolic compounds such as 4,4-dihydroxy-diphenyl methane from raw horseradish (Zhou et al., 1980, Acta botanica Yunnanica. 2:370-372). In addition, it was reported that the antioxidant power of Chunma extract using perilla oil as a substrate was higher than that of BHT, a synthetic antioxidant, and that the antioxidant power increased as the concentration of Chunma extract increased. reported that there is It has been reported that p-hydroxybenzyl alcohol and vanillin, which are the main components of Chunma, have strong antioxidant effects in DPPH, superoxide, and hydroxyl radical scavenging ability, and have excellent effects as antioxidants in vitro and in vivo. As such, multifaceted research is required to use Chunma as a food material. Recently, various studies on physiological activity are being conducted by fermenting natural products or processing enzymes. It is lacking.
천마는 예로부터 뇌혈관, 심혈관질환에 사용되었으며, 여러 연구에서도 그 기능성과 유효성을 인정받고 있는 작물로 특히 노화과정에서 발생하는 여러 질환에 다양한 도움을 준다고 알려져 있다. 이러한 천마제품은 스트레스가 많은 현대인들에게 유효하게 작용할 수 있을 것이다. 특히 아시아권 국가에서는 이러한 천마의 유효성에 대한 관심과 이해가 이미 일부 형성되어 있어 신뢰할 수 있는 제품으로 접근한다면 시장성을 높일 수 있다고 본다.Chunma has been used for cerebrovascular and cardiovascular diseases since ancient times, and its functionality and effectiveness have been recognized in several studies. These Chunma products can work effectively for modern people who have a lot of stress. In particular, in Asian countries, interest and understanding of the effectiveness of Chunma has already been partially formed, so if you approach it as a reliable product, you can increase the marketability.
천마는 난초과의 다년생 약용식물로 유효성분인 가스트로딘은 뇌질환개선 및 혈압조절에 탁월하고 에르고티오닌 성분의 함량은 영지버섯류의 수십배에 달한다. 당사 천마 제품은 전통적인 천마의 효능을 바탕으로 강화된 기능성과 믿을 수 있는 원료로 개발, 생산되었다.Chunma is a perennial medicinal plant of the orchid family, and its active ingredient, gastrodin, is excellent for improving brain diseases and controlling blood pressure. Our Chunma products have been developed and produced with enhanced functionality and reliable raw materials based on the efficacy of traditional Chunma.
그러나 천마 특유의 불쾌한 향과 맛으로 인해 거부감을 나타내는 소비자가 많아 소비층이 다양화 되지 못하고, 휴대와 섭취의 편의성이 떨어져 유사제품 시장에서 두각을 나타내기 어려운 상황이다.However, due to the unpleasant smell and taste unique to Chunma, there are many consumers who show objection to the consumer base, so it is difficult to stand out in the market for similar products due to the lack of convenience in portability and consumption.
천마의 주효능은 뇌혈관, 심혈관, 기억력 및 인지능력 개선기능 등으로, 고령사회의 도래로 심화된 만성질환 예방과 고령생활을 위한 식품개발에 대한 수요증가에 부합하는 약용식물이다. 또한 식품사업 및 헬스케어 트랜드도 기능성강화와 고령친화제품에 주목하고 관련 제품들이 개발, 출시되고 있다.The main effect of Chunma is to improve cerebrovascular, cardiovascular, memory and cognitive abilities, etc., and it is a medicinal plant that meets the growing demand for food development for the elderly and the prevention of chronic diseases that have worsened with the advent of an aging society. In addition, food business and healthcare trends are paying attention to functional enhancement and age-friendly products, and related products are being developed and launched.
천마 등의 한방약용자원의 경우 원물로의 판로와 수익, 수출 등은 한정적이지만 신기술을 접목시켜 개발한 가공품의 경우 다양한 판로 모색과 수출개척에도 유리하다. 이미 그 유효성에 관한 검증은 이루어진 천마에 발효기술을 접목하여 기능성을 강화시키고 식이성을 향상시킬 수 있다면 소비자의 접근성을 높일 수 있는 기회가 될 것이다. 이러한 제품연구와 개발로 좀 더 높은 부가가치를 얻을 수 있다고 본다.In the case of herbal medicinal resources such as Chunma, the market for raw materials, profits, and exports are limited, but in the case of processed products developed by grafting new technologies, it is advantageous for exploring various markets and pioneering exports. If fermentation technology can be applied to cheonma, which has already been verified on its effectiveness, to enhance functionality and improve diet, it will be an opportunity to increase consumer accessibility. I believe that higher added value can be obtained through such product research and development.
하수오(何首烏, Polygonummultiflorum Thunberg)는 마디풀과에 속하는 다년생 초본인 3~4년 된 하수오의 괴근(塊根)을 채취하여 건조한 것이다. 여기에서, 하수오는 적하수오(赤何首烏)를 의미하는 것으로서, 우리나라 대한약전외한약규격집에서 적하수오(赤何首烏)를 하수오로, 백하수오(白何首烏)를 백수오로 구분하여 규정하고 있는 것에 따른다. 하수오의 맛은 쓰고 달고 떫으며 성질은 약간 온하며 간과 신장을 보하고 혈을 자양하며 풍을 제거하는 효능이 있어서, 만성 간염, 유정 등을 치료하는데 사용한다. 서양의학적 관점에서 보면, chrysophanol, emodin, lecithin등 성분들을 함유하고 있는 하수오는 혈당을 하강시키고 항균 작용이 있으며 혈청 콜레스테롤을 낮추는 효능도 있다.Polygonum multiflorum Thunberg (何首烏, Polygonum multiflorum Thunberg) is a perennial herb belonging to the family Candidae, which is collected and dried from the tuberous roots of 3 to 4 years old Haushu. Here, Hasuo means red and white, and it follows that in the Korean Pharmacopoeia and Korean Medicine Specifications, red and white are divided into white and white. The taste is bitter, sweet, and astringent, and the nature is slightly mild. It has the effect of nourishing the liver and kidneys, nourishing the blood, and removing wind, so it is used to treat chronic hepatitis and oil wells. From a Western medical point of view, sewage containing ingredients such as chrysophanol, emodin, and lecithin lowers blood sugar, has antibacterial action, and has the effect of lowering serum cholesterol.
하수오(Pleuropterus multiflorus)는 중국에서 들어와 오랫동안 재배되어온 약용식물로, 전체에 털이 없고, 뿌리는 땅 속으로 뻗으면서 때때로 둥근 덩이뿌리를 형성한다. 잎은 어긋나고 자루가 있으며 길이 3∼6㎝, 너비 2.5∼4.5㎝로서 끝이 뾰족하고 밑부분이 심장형인 난상심장형을 하고 있다. 꽃은 8∼9월에 백색으로 피며 가지 끝에 원추화서를 이룬다. 과실은 수과(瘦果:볍씨와 같이 과피가 목질 또는 혁질을 이루고 속에 1개의 씨가 들어있는 열매)이다. 한방에서는 덩이뿌리를 약재로 사용한다.Pleuropterus multiflorus is a medicinal plant that has been cultivated for a long time since it came from China. The leaves are alternate phyllotaxis, with a stalk, 3-6 cm long and 2.5-4.5 cm wide, with a sharp tip and an egg-shaped heart shape with a heart-shaped bottom. The flowers are white in August-September and form a panicle at the end of the branch. Fruit is aqueous (瘦果: a fruit with a woody or leathery rind like rice seeds and one seed inside). In oriental medicine, the tuber root is used as a medicine.
약성은 온(溫)하고 감고(甘苦)하며 조삽(燥澁:파슬파슬함)하다. 강장ㆍ강정ㆍ양혈(養血)ㆍ보간ㆍ거풍ㆍ소종의 효능이 있는 것으로 알려져 있다. 신체허약ㆍ요통ㆍ동맥경화ㆍ양위(陽萎)ㆍ고혈압ㆍ만성간염ㆍ결핵성임파선염ㆍ장염ㆍ옹종(癰腫)ㆍ변비 등의 증상에 치료제로 쓴다.Weakness is mild, cold, and coarse. It is known to have the effects of tonic, gangjeong, yanghyeol, interpolation, geopung, and small bell. It is used as a treatment for symptoms such as physical weakness, low back pain, arteriosclerosis, positive gastric emptying, high blood pressure, chronic hepatitis, tuberculosis lymphadenitis, enteritis, onset swelling, and constipation.
그러나 약용식물 추출물이 세포 대사에 독성을 나타내는 경우가 종종 있는 것으로 보고되어 있어 버섯균사체로 발효시킨 약용식물 추출물에 관한 관심이 증가되고 있다. 발효에 의해 많은 효소가 생성되며 생산되는 효소 중에서 항산화 효소가 많이 생산되므로 노화 예방, 피부 개선 등에 효과가 있으며 미생물의 발효산물은 독성과 부작용을 유발하는 원인 물질을 해결할 수 있을 뿐만 아니라 체질, 가령 체질에 따른 부작용이나 약재의 알러지 문제를 개선할 수 있는 것으로 보고되고 있다.However, it has been reported that medicinal plant extracts are often toxic to cell metabolism, so interest in medicinal plant extracts fermented with mushroom mycelium is increasing. Fermentation produces many enzymes, and among the produced enzymes, many antioxidant enzymes are produced, so it is effective in preventing aging and improving skin. It is reported to be able to improve the side effects or allergy to drugs.
인삼(Panax Ginseng C. A. Meyer)은 五加科(두릅나무과 ; Araliaceae)에 속한 다년생 초목으로 뿌리를 약으로 사용하며, 가공 방법에 따라 말린 것을 백삼, 수증기 또는 기타 방법으로 쪄서 건조한 것을 홍삼이라고 한다. 최근 들어 삼에 대한 포제방법에 따라 효능이 달라질 수 있음이 보고되면서 인삼의 새로운 가공방법이 많이 나타나고 있는데 주로 열처리, 산(acid), 효소처리 및 미생물을 이용한 발효처리 등에 의해 인삼의 맞춤형 제품들이 출시되고 있다. 특히 미생물 및 효소를 이용한 발효를 이용하여 특정성분을 강화시킨 가공인삼이 최근 들어 기능성식품으로 주목을 받고 있다.Ginseng (Panax Ginseng C. A. Meyer) is a perennial plant belonging to the Araliaceae family, and its roots are used as medicine. Recently, as it has been reported that the efficacy of ginseng may vary depending on the method of preparation, new processing methods of ginseng are emerging. is becoming In particular, processed ginseng, in which specific ingredients are fortified using fermentation using microorganisms and enzymes, has recently been attracting attention as a functional food.
산양삼의 경우, 중국의 도홍경(488-496)의 수정한 '신농본초경'에 인삼은 "오장을 보하고, 정신을 안정시키며, 혼백을 고정 경계를 멈추게 하고, 외부로부터 침입하는 사기를 제거하여 주며, 눈을 밝게 하고 마음을 열어 더욱 지혜롭게 하며 오래 복용하면 몸이 가벼워지고 장수한다"고 되어 있다. 또한 명의별록, 본초강목에도 인삼의 효능을 집약 수록된 바 있고, 조선의 동의보감에 이들을 인용하여 적고 있다.In the case of wild ginseng, in the revised 'Shennong Bon Chagyeong' of China's Tao Hongqing (488-496), ginseng is "to nourish the five intestines, to stabilize the mind, to fix the soul and to stop the vigilance, and to remove the intrusion from outside. It brightens the eyes, opens the mind, and makes you smarter. If you take it for a long time, your body will become lighter and you will live longer." In addition, the efficacy of ginseng has been intensively recorded in Myungbyeolrok and Bonchogangmok, and they are cited and written in Donguibogam of the Joseon Dynasty.
삼은 독성이 없어 장기간 복용해도 해가 없으며 불로장생에 도움을 주는 "상약"의 대표적인 약으로 단독, 또는 한방 구성의 생약으로 처방약의 군약으로 이용되고, 주로 기허(서양의학적으로 생리기능이 저하된 상태)를 치료하는 중요한 보기약으로 쓰인다.Since ginseng is non-toxic, it is harmless even if taken for a long period of time. It is a representative drug of “sangyak” that helps in immortality and longevity. It is used alone or as a herbal medicine composed of oriental medicine and is used as a group medicine for prescription drugs. It is used as an important auxiliary agent in the treatment of
나아가 한방의학 연구에 따른 브레이크만 박사에 의하면, 산삼은 스트레스 해소, 알콜해독, 당뇨병, 암, 동맥경화증, 고혈압, 간 질환, 빈혈에 효과가 있다고 발표했고, 산삼은 간장제로서 피로 회복 및 수술이나 질병 후 기력회복에 좋고 노약자에게 좋은 보약제이다.Furthermore, according to Dr. Breakman according to Korean herbal medicine research, wild ginseng is effective in relieving stress, detoxifying alcohol, diabetes, cancer, arteriosclerosis, high blood pressure, liver disease, and anemia. It is good for recovering energy after illness and is a good medicine for the elderly.
현대 과학 연구결과에 의하면 암, 당뇨, 동맥경화 등 성인병에 효능이 있다는 연구결과가 나왔다. 즉, 피로회복, 체력증진, 빈혈, 저혈압, 심장쇠약, 노이로제, 자율신경실조, 폐결핵, 천식, 위장염, 설사, 변비, 식용부진, 당뇨병, 옹절, 피부병 및 거친 살갗에 탁월한 효과가 있음이 입증되었다.According to the results of modern scientific research, research results have come out that it is effective in adult diseases such as cancer, diabetes, and arteriosclerosis. That is, it has been proven to have excellent effects on recovery from fatigue, physical strength, anemia, hypotension, heart weakness, neurosis, autonomic nervous system, pulmonary tuberculosis, asthma, gastroenteritis, diarrhea, constipation, poor eating, diabetes, intolerance, skin disease and rough skin. .
산양삼에 들어있는 사포닌 및 비사포닌계 물질(Panacen, 다당류, 아미노산 유도체, 폴리아세틸렌 유도체, 페놀화합물)은 약리활성이 우수하고 자유라디칼(free radical) 제거에 탁월한 효능을 가져 항암, 혈압강하, 지질강하, 간독성 제거 등의 목적으로 다양하게 이용된다. 이처럼 우수 효능을 지닌 산양삼의 주요 약리성분은 PD(proto panaxadiol), PT(proto panaxatriol)계로 나누어지며, 산양삼에 포함된 진세노사이드(ginsenosides)의 함량은 일반 인삼에 비해 최대 3 내지 4배 더 높은 것으로 알려져 있다.Saponin and non-saponin substances (Panacen, polysaccharides, amino acid derivatives, polyacetylene derivatives, phenol compounds) contained in wild ginseng have excellent pharmacological activity and have excellent efficacy in removing free radicals, thereby reducing anticancer, blood pressure, and lipid lowering properties. , and is used for various purposes such as removal of hepatotoxicity. The major pharmacological components of wild ginseng with excellent efficacy are divided into PD (proto panaxadiol) and PT (proto panaxatriol), and the content of ginsenosides contained in wild ginseng is up to 3 to 4 times higher than that of general ginseng. it is known
한편, 점점 가속화되고 있는 고령사회진행으로 심화된 만성질환에 대한 우려와 건강한 노후생활을 위한 기대를 반영한 식품개발에 대한 수요가 증가하는 추세이다. 이에, 식품산업 및 헬스케어 트랜드도 기능성강화와 고령친화제품에 주목하고 관련제품들이 개발, 출시되고 있다.On the other hand, the demand for food development that reflects the concerns about chronic diseases, which is aggravated by the accelerating aging of society and the expectations for a healthy old life, is on the rise. Accordingly, food industry and healthcare trends are also paying attention to functional enhancement and age-friendly products, and related products are being developed and released.
건강식품 원료를 제조하는 방법은 끓여 졸이거나 건조하여 생약을 이용하는 방법이 일반적이다. 이러한 방법에서는 가열에 의한 유효성분의 소멸이 많아 생약이 본래 가지고 있는 효과를 기대하기 어렵고, 더욱이 건조생약을 그대로 사용할 경우 대부분의 생약은 체내에서 흡수될 수 없는 산화형 NAD를 가지고, 체내 섭취한 후, 환원형 NAD로 변환되어 흡수되지만 변환된 환원형 NAD 성분은 다시 산화형 NAD로 재변환되어 대부분 유효성분이 체외로 배출된다. The general method of manufacturing health food raw materials is to boil or boil or dry to use herbal medicines. In this method, it is difficult to expect the original effect of the herbal medicine because the active ingredient disappears due to heating in this method. Moreover, when the dried herbal medicine is used as it is, most herbal medicines have oxidized NAD that cannot be absorbed by the body, and after ingestion , is converted into reduced NAD and absorbed, but the converted reduced NAD component is reconverted back to oxidized NAD and most of the active ingredients are excreted outside the body.
이러한 결점을 보충하기 위하여, 발효미생물을 이용하여 전분함유가 많은 곡물원료를 분쇄하고, 발효공정처리에 의해 환원형 성분으로 변환함으로써 기능성 건강식품을 제조하여야 할 필요성이 크다. 미생물의 분해ㆍ대사ㆍ생성을 이용한 반응은 고온ㆍ고압을 필요로 하지 않는 자원절약 및 에너지 절약형이고, 반응선택성이 크고, 간단한 장치로 물질생산이 가능하다는 등의 특징을 가지고 있으므로 발효미생물을 이용하여 천마와 하수오의 기능성 성분을 보다 흡수가 용이한 기능성의 발효 식품으로 이용할 수 있다. In order to compensate for these drawbacks, there is a great need to manufacture functional health foods by using fermented microorganisms to grind grain raw materials containing a lot of starch and converting them into reduced ingredients by fermentation process treatment. The reaction using the decomposition, metabolism, and production of microorganisms is a resource-saving and energy-saving type that does not require high temperature and high pressure, has large reaction selectivity, and has features such as being able to produce substances with a simple device. The functional ingredients of Chunma and Hausoo can be used as functional fermented foods that are easier to absorb.
이에, 본 발명자들은 우리나라에서 자생하고 있는 한방 생약재 중 쉽게 구할 수 있고, 여러 가지 생리활성 기능이 알려진 천마, 하수오 및 산양삼에 발효균을 발효시켜 얻은 약제의 추출물로부터 항산화 효과와 tyrosinase 활성 억제 등에 의한 기능성과 액상으로서의 기호도가 증진됨을 확인함으로써, 본 발명을 완성하였다.Accordingly, the inventors of the present inventors have found that from extracts of drugs obtained by fermenting fermented bacteria on cheonma, sauerkraut, and wild ginseng, which are readily available among oriental herbal medicines that are native to Korea, and which are known for their various physiologically active functions, the antioxidant effect and functionality by inhibition of tyrosinase activity, etc. The present invention was completed by confirming that the preference as a liquid was improved.
본 발명의 목적은 천마, 하수오 및 산양삼을 혼합하고 여기에 유효미생물을 접종, 발효 분해 처리함으로써, 미생물의 기능인 대사, 발효, 분해 능력을 활용하여 그 과정 화학반응에 의해 생성되는 성분을 이용하여 환원형 성분으로 변환되는 기능성 액상 건강식품의 제조방법을 제공하는 것이다.The object of the present invention is to reduce using the components generated by the chemical reaction of the process by using the metabolism, fermentation, and decomposition ability, which are the functions of microorganisms, by mixing cheonma, ginseng and wild ginseng, inoculating and fermenting and decomposing effective microorganisms therein. It is to provide a manufacturing method of a functional liquid health food that is converted into a type component.
상기 목적을 달성하기 위하여, 본 발명은 1) 천마를 슬라이스 하고 찌고 말리는 증폭 과정을 반복한 후 건조시키는 단계; 2) 하수오와 산양삼을 찌고 말리는 증폭 과정을 반복하는 단계; 3) 상기 1) 천마 및 2) 하수오를 혼합하고 상기 약재를 분말화하는 단계; 4) 상기 분말 약재에 건조하고 분쇄된 오가피 및 비타민 어린잎을 혼합하는 단계; 5) 상기 분말을 생수로 반죽하고 당을 첨가하여 배양액을 제조하는 단계; 6) 상기 배양액을 유산균 발효균주로 발효시키는 단계; 및 7) 상기 발효물을 여과하고 농축하여 액상 제품을 제조하는 단계;를 포함하는 기능성 액상 건강식품의 제조 방법을 제공한다.In order to achieve the above object, the present invention comprises the steps of: 1) drying after repeating the amplification process of slicing and steaming and drying Chunma; 2) repeating the amplification process of steaming and drying ginseng and wild ginseng; 3) mixing the 1) Chunma and 2) Sauer and pulverizing the medicine; 4) mixing the dried and pulverized cucumber and vitamin young leaves with the powdered medicine; 5) preparing a culture solution by kneading the powder with mineral water and adding sugar; 6) fermenting the culture solution with a lactic acid bacteria fermenting strain; And 7) filtering and concentrating the fermented product to prepare a liquid product; provides a method for producing a functional liquid health food comprising.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 기능성 액상 건강식품의 제조 방법에 있어서, 상기 유산균 발효균주는 락토바실러스 플란타룸(Lactobacillus plantarum) 및/또는 락토바실러스 애시도필러스(Lactobacillus acidophillus)인 것이 바람직하고, 락토바실러스 플란타룸(Lactobacillus plantarum) KCTC 3108 및/또는 락토바실러스 애시도필러스(Lactobacillus acidophillus) KCTC 3140인 것이 가장 바람직하다.In the manufacturing method of the functional liquid health food of the present invention, the lactic acid bacteria fermented strain is Lactobacillus plantarum ( Lactobacillus plantarum ) and / or Lactobacillus acidophilus ( Lactobacillus acidophillus ) Preferably, Lactobacillus plantarum ( Lactobacillus plantarum ) KCTC 3108 and / or Lactobacillus acidophilus ( Lactobacillus acidophillus ) KCTC 3140 is most preferred.
또한, 본 발명의 기능성 액상 건강식품의 제조 방법에 있어서, 상기 천마 : 하수오 : 산양삼의 함량은 1: 0.5~2 : 0.5~2의 중량비인 것이 바람직하다.In addition, in the manufacturing method of the functional liquid health food of the present invention, the content of cheonma: succulent: wild ginseng is preferably 1: 0.5-2: 0.5-2 by weight.
또한, 본 발명의 기능성 액상 건강식품의 제조 방법에 있어서, 상기 약재는 구기자, 두충, 울금, 둥굴레, 말토덱스트린, 현미, 보리, 검정콩, 들깨 및 검정깨로 이루어진 군중에서 선택된 1종 이상의 추가적 성분의 분말을 포함하는 것이 바람직하고, 상기 찌고 말리는 증폭 과정은 2~4회 수행하고, 발효 균주의 배양은 30~35℃에서 1~3일 동안 이루어지는 것이고, 상기 여과와 농축으로 55° Brix의 액상이 달성되고, 상기 당은 설탕인 것이 바람직하다.In addition, in the manufacturing method of the functional liquid health food of the present invention, the medicinal material is one or more additional ingredients selected from the group consisting of goji berry, turmeric, turmeric, maltodextrin, brown rice, barley, black soybean, perilla and black sesame. It is preferable to include a powder, and the steaming and drying amplification process is performed 2 to 4 times, and the culture of the fermentation strain is made at 30 to 35 ° C. for 1 to 3 days, and 55 ° Brix liquid phase is obtained by the filtration and concentration. is achieved, and it is preferred that the sugar is a sugar.
상기 2) 단계의 증폭은 2~4회 수행하여 하수오 및 산양삼의 최적 기능성을 생성하고, 상기 6) 단계의 발효는 30~35℃에서 24시간 동안 이루어짐으로서 식품의 기능성과 미감을 향상시킨다. 또한, 상기 5) 단계의 추가 당으로 설탕을 사용하여 미감을 향상시킨다.The amplification of step 2) is performed 2 to 4 times to produce optimal functionality of ginseng and wild ginseng, and fermentation in step 6) is performed at 30-35° C. for 24 hours to improve the functionality and aesthetics of food. In addition, the aesthetic feeling is improved by using sugar as the additional sugar in step 5).
상기 당으로 설탕을 사용하는 것이 발효균의 발효 증진과 미감 향상에 도움이 된다. 또한, 상기 약 55° Brix로 농축을 달성하여야 식품 기능성과 미감 향상을 달성할 수 있다. 천마, 하수오, 산양삼의 함량은 1: 0.5~2 : 0.5~2의 중량비에서 최적의 기능성을 달성하며, 상기 천마, 하수오와 산양삼 이외에 울금, 둥굴레, 말토덱스트린이나 현미, 보리, 검정콩, 들깨 및 검정깨와 같은 곡물을 추가적으로 함유시켜 그 기능성을 향상시킬 수 있다.The use of sugar as the sugar helps to promote fermentation of fermented bacteria and improve taste. In addition, it is possible to achieve food functionality and aesthetic improvement only when the concentration is achieved at about 55° Brix. The content of cheonma, sauerkraut, and wild ginseng achieves optimal functionality at a weight ratio of 1: 0.5-2: 0.5-2. The functionality can be improved by additionally containing grains such as sesame seeds.
발효란 미생물의 생리활동에 의해 일어나는 화학변화로서 유기물이 산화, 환원 또는 분해에 의하여 인간생활에 유익한 다른 물질로 변화되는 현상으로, 인류가 기원전 3,000년경부터 각 지역의 토착 미생물이 식품원료에 자연 접종되는 과정을 통해 섭취하면서 고유한 음식문화를 형성하여 왔고, 최근에는 건강기능성 장수식품으로 인식되고 있다(Goldin BR. Br. J. Nutr. 1998; 80: 203-207). Fermentation is a chemical change that occurs due to the physiological activities of microorganisms, and is a phenomenon in which organic matter is transformed into other substances beneficial to human life by oxidation, reduction or decomposition. It has formed a unique food culture by ingesting it through the process of becoming, and recently it is recognized as a health functional food for longevity (Goldin BR. Br. J. Nutr. 1998; 80: 203-207).
특히 Lactobacilli 및 Bifidobacterium과 같은 유산균들은 사람의 장내에서 우세균으로 분포하면서 체내 유익균의 성장을 촉진하여 위장기능의 개선, 체내 콜레스테롤 흡수저해, 면역조절, 영양소의 흡수 및 이용률을 높이는 등 다양한 질병 예방효과와 생리조절작용을 하는 것으로 알려져 있다(Fuller R. et al., J. Applied Bacteriology. 1989; 66: 365-378). 인삼에 있어서도 ginsenoside의 분해를 통한 흡수과정에 관여하여 특정 산물을 만들어낼 수 있음이 최근 연구를 통해 밝혀진 바 있다.In particular, lactic acid bacteria such as Lactobacilli and Bifidobacterium are distributed as dominant bacteria in the human intestine and promote the growth of beneficial bacteria in the body to improve gastrointestinal function, inhibit cholesterol absorption in the body, regulate immunity, and increase the absorption and utilization rate of nutrients and prevent various diseases. It is known to have a modulating action (Fuller R. et al., J. Applied Bacteriology. 1989; 66: 365-378). In ginseng, it has been found through recent research that it can produce specific products by participating in the absorption process through the decomposition of ginsenoside.
본 발명을 통해 천마의 최적화된 공정기술을 확립하고 천마 고유의 불쾌한 미식감 극복 및 흡수율 개선을 통해 노년층에 국한된 기존 시장을 전 연령층으로 확대할 것이다. 본 제품의 전통적인 유효성 검증을 바탕으로 한방원료에 관한 관심이 큰 아시아권 국가, 특히 한국 제품에 대한 신뢰가 큰 동남아국을 대상으로 한 수출시장의 확대를 꾀할 수 있다. Through the present invention, we will establish the optimized process technology of Chunma and expand the existing market limited to the elderly to all age groups by overcoming the unique unpleasant taste of Chunma and improving the absorption rate. Based on the traditional validation of this product, it is possible to expand the export market for Asian countries with a large interest in oriental medicine raw materials, especially Southeast Asian countries with high trust in Korean products.
본 발명은 발효기술을 이용한 항노화소재 개발, 천마에 고온숙성 발효기술을 접목시켜 새로운 형태의 천연물질 항노화소재를 개발, 섭취편의성을 향상시킨 제형의 개발, 바쁜 현대인의 요구에 부합하는 편의성을 향상시킨 제형의 제품 개발 등으로 확대될 수 있다.The present invention is to develop an anti-aging material using fermentation technology, develop a new type of natural anti-aging material by grafting high-temperature aging fermentation technology to cheonma, develop a formulation with improved intake convenience, and provide convenience to meet the needs of busy modern people. It can be expanded to product development of improved formulations, etc.
이상과 같이, 본 발명의 천마는 심혈관, 뇌혈관의 피를 맑게 해주어 순환기에 도움이 되고, 하수오는 혈관 확장 기능이 있으며, 산양삼은 면역력 증강 및 병후 기력회복 효과가 있으며, 인공 합성물을 전혀 첨가하지 않고, 천마, 하수오와 산양삼의 우수한 영양 성분과 더불어 황국균과 같은 발효 균주에 의한 발효로 다양한 아미노산류, 비타민류 등의 성분들이 어우러져 영양가를 더욱 증가시키고 생체 신진대사를 촉진시킨다. 또한, 비타민 어린잎을 이용하므로 항산화활성이 매우 우수하며, 피로 지표물질을 경감시켜 피로회복용 기능성 식품 제조에 효과적이다. 또한, 암세포의 성장 및 전이억제 효과가 보고된 ginsenoside Rh2, ginsenoside Rg3를 대량 함유한 산양삼의 ginsenoside 함량이 발효과정에 의해 변화됨을 확인하였다.As described above, the cheonma of the present invention purifies the blood of the cardiovascular and cerebrovascular vessels, which helps the circulation, the sewage has a vasodilator function, and the wild ginseng has the effect of enhancing immunity and recovering energy after illness, and no artificial compounds are added. Fermentation by fermented strains such as Hwanggukgyun, along with the excellent nutritional ingredients of Chunma, Haushu and wild ginseng, harmonizes with various amino acids and vitamins to further increase the nutritional value and promote metabolism in the body. In addition, since vitamin young leaves are used, antioxidant activity is very good, and it is effective in manufacturing functional foods for fatigue recovery by reducing fatigue index substances. In addition, it was confirmed that the ginsenoside content of wild ginseng containing a large amount of ginsenoside Rh2 and ginsenoside Rg3, which has been reported to inhibit the growth and metastasis of cancer cells, was changed by the fermentation process.
아울러, 천마, 하수오, 산양삼이 가지고 있는 특유의 강한 향과 맛을 순화시켜 이미, 이취가 없는 액상으로 제조되어 기호성이 크게 향상되고, 소화력이 우수하며 복용감도 훨씬 좋아지며, 순환기나 혈관 질환과 같은 각종 질병의 예방에 효과적이다.In addition, by purifying the unique strong scent and taste possessed by Chunma, Hsuo, and wild ginseng, it has already been prepared in a liquid form without odor, greatly improving palatability, excellent digestion, and much better handling, such as circulatory and vascular diseases. It is effective in preventing various diseases.
도 1은 실시예 1에 따른 발효 후, 여과 및 농축하기 전의 액상 조성물을 나타낸 사진이다.1 is a photograph showing a liquid composition after fermentation according to Example 1, before filtration and concentration.
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .
<실시예 1> 액상 조성물의 제조 1<Example 1> Preparation of liquid composition 1
본 실험에 사용한 발효 균주로 한국생명공학연구원 생물자원센터(KCTC)에서 분양받은 락토바실러스 플란타룸(Lactobacillus plantarum) KCTC 3108과 락토바실러스 애시도필러스(Lactobacillus acidophillus) KCTC 3140를 사용하였다. 배양은 맥아배지를 이용하여 멸균기(AC-60, Han Yang Scientific Equipment, Seoul, Korea)에서 121℃에 15분간 멸균을 한 후 발효균을 접종하였고 진탕배양기(VS-8480SR, Scientific, Bucheon, Korea)에 넣은 후 150 rpm에서 34℃로 3일 동안 배양하여 이를 액체종균으로 사용하였다.As fermentation strains used in this experiment, Lactobacillus plantarum KCTC 3108 and Lactobacillus acidophillus KCTC 3140 acquired from the Korea Research Institute of Bioscience and Biotechnology Biological Resources Center (KCTC) were used. The culture was sterilized at 121℃ for 15 minutes in a sterilizer (AC-60, Han Yang Scientific Equipment, Seoul, Korea) using malt medium, and then inoculated with fermented bacteria, and placed in a shaking incubator (VS-8480SR, Scientific, Bucheon, Korea). After incubation at 150 rpm at 34° C. for 3 days, it was used as a liquid seed culture.
천마는 본 출원인인 백초영농조합법인이 자체 재배하여 수확한 후 물로 수세하여 표면 흙과 이물질을 제거한 다음 일정 두께로 얇게 슬라이스하고 찌고 말리는 증폭 과정을 3회 반복한 후, 50℃ 열풍건조기를 이용하여 건조한 시료를 분쇄하여 분말화시켜 약재를 제조하였다. 또한, 하수오와 산양삼 모두 본 출원이 자체 재배하여 수확한 것을 사용하였으며, 이때 수확된 산양삼은 수령 8-9 년생을 36 뿌리 무작위로 선정하여 사용하였다. 하수오와 산양삼은 사용 전 흐르는 물에 30초간 수세하여 불순물을 제거한 후, 찌고 말리는 증폭 과정을 3회 반복하였다.Chunma is grown and harvested by the present applicant, Baekcho Agricultural Cooperative Corporation, and then washed with water to remove surface soil and foreign substances, then sliced thinly to a certain thickness, steamed and dried, and the amplification process is repeated 3 times, followed by a 50℃ hot air dryer. The dried sample was pulverized and pulverized to prepare a medicine. In addition, both H. ginseng and wild ginseng were grown and harvested by the present application, and the harvested wild ginseng was used by randomly selecting 36 roots from 8 to 9 years of age. Before use, the ginseng and wild ginseng were washed with running water for 30 seconds to remove impurities, and then the amplification process of steaming and drying was repeated 3 times.
산양삼을 가공할 때 산양삼의 잔가지들도 모두 떨어지지 않도록 주의해야 한다. 이 산양삼의 잔가지에도 많은 양의 인체에 유용한 성분이 포함되어 있기 때문이다. 그리고 상기 산양삼에서 물기를 없애는 건조의 단계를 거쳐 분쇄를 한다. 즉, -40~-1℃로 65-80시간 동결건조하여 함수율이 2-7% 될 때까지 유지한 후 70-100메쉬로 분쇄하는 것이다.When processing wild ginseng, be careful not to drop all the twigs of wild ginseng. This is because the twigs of this wild ginseng contain a large amount of useful ingredients for the human body. Then, the wild ginseng is pulverized through a drying step to remove moisture from the wild ginseng. That is, freeze-drying at -40 to -1°C for 65-80 hours, maintaining it until the moisture content becomes 2-7%, and then pulverizing to 70-100 mesh.
상기 제조한 천마, 하수오와 산양삼을 혼합하고 이들을 분말화시켜 약재를 제조하였다. 상기 분말 약재 100중량부에 생수 600중량부를 첨가하여 반죽하고 여기에 설탕 30중량부를 첨가한 후 발효균으로 발효시켰다. The above-prepared Chunma, Hasuo, and wild ginseng were mixed and these were powdered to prepare medicinal materials. 600 parts by weight of mineral water was added to 100 parts by weight of the powdered medicinal material, kneaded, and 30 parts by weight of sugar was added thereto and fermented with fermented bacteria.
상기 분말 약재 100중량부에 생수 600중량부를 첨가하여 반죽하고 여기에 설탕 30중량부를 첨가한 후 발효균으로 발효시켰다. 600 parts by weight of mineral water was added to 100 parts by weight of the powdered medicinal material, kneaded, and 30 parts by weight of sugar was added thereto and fermented with fermented bacteria.
구체적으로, 설탕 함유 약재 100 g을 각각 850 mL polypropylene bottle에 넣고 121℃에서 20분간 고압멸균한 후 상온에서 냉각하였다. 상기에서 조제된 발효균 액체종균 20ml을 상기 약재에 무균상태에서 접종한 후 멸균마개를 고정시켜 오염을 방지하였다. 발효는 34℃, 상대습도 90%의 배양기에서 2일 동안 진행하였다. 균사체 배양 정도는 육안으로 판단하였으며, 배지에 성장되는 균사체의 양에 따라 생장 우수(++), 생장 양호(+), 및 생장 불량(-)로 나타내었다.Specifically, 100 g of sugar-containing medicinal materials were placed in an 850 mL polypropylene bottle, sterilized at 121° C. for 20 minutes, and then cooled at room temperature. After inoculating 20 ml of the fermented liquid starter prepared above in an aseptic condition to the above medicine, a sterile stopper was fixed to prevent contamination. Fermentation was carried out for 2 days in an incubator at 34° C. and 90% relative humidity. The degree of mycelial culture was visually judged, and it was expressed as excellent (++), good (+), and poor growth (-) depending on the amount of mycelium grown in the medium.
2일 동안 발효 후 (도 1) 상기 발효물을 여과하고 55° Brix로 농축하여 액상 조성물을 제조하였다. After fermentation for 2 days (FIG. 1), the fermented product was filtered and concentrated to 55° Brix to prepare a liquid composition.
상기 락토바실러스 플란타룸(Lactobacillus plantarum) 및 락토바실러스 애시도필러스(Lactobacillus acidophillus)은 약 90가지의 유효하게 명명된 종 또는 서브(sub)종을 포함하는 락토바실러스의 방대하고 비교적 다양한 속(genus)중의 박테리아 종이다. 전통적으로, 락토바실러스 spp.는 이들의 발효 능력에 따라서 세가지의 기능성 그룹으로 구분된다: 절대적인 정상발효(그룹 Ⅰ), 임의의 이상발효(그룹 Ⅱ) 및 절대적인 이상발효(그룹 Ⅲ).The Lactobacillus plantarum (Lactobacillus plantarum) and Lactobacillus acidophilus ( Lactobacillus acidophillus ) is a vast and relatively diverse genus of Lactobacillus, including about 90 effectively named species or subspecies ) of the bacterial species. Traditionally, Lactobacillus spp. are divided into three functional groups according to their fermentative capacity: absolute normal fermentation (group I), random aberrant fermentation (group II) and absolute aberrant fermentation (group III).
본 발명의 락토바실러스 플란타룸(Lactobacillus plantarum) 및 락토바실러스 애시도필러스(Lactobacillus acidophillus)은 공지의 락토바실러스 플란타룸, 락토바실러스 애시도필러 균주라면 제한되지 않고 본 발명에 적용될 수 있지만, 바람직하게 락토바실러스 플란타룸 (Lactobacillus plantarum) KCTC 3108 및/또는 락토바실러스 애시도필러스(Lactobacillus acidophillus) KCTC 3140 균주일 수 있다.Lactobacillus plantarum and Lactobacillus acidophillus of the present invention are not limited as long as the known Lactobacillus plantarum and Lactobacillus acidophilus strains are not limited and can be applied to the present invention, but preferably Lactobacillus plantarum ( Lactobacillus plantarum ) KCTC 3108 and / or Lactobacillus acidophilus ( Lactobacillus acidophillus ) It may be a KCTC 3140 strain.
<실시예 2> 액상 조성물의 제조 2<Example 2> Preparation of liquid composition 2
상기 실시예 1의 약재 분말 100중량부에 오가피와 비타민 어린잎 20중량부를 정선하고 세척하며 건조해서 분쇄하여 혼합하였다. 이하 과정은 상기 실시예 1과 동일하다.Selected, washed, dried, pulverized, and mixed 20 parts by weight of oga skin and vitamin young leaves in 100 parts by weight of the medicinal powder of Example 1. The following process is the same as in Example 1.
오가피는 중국 전통한방에서 가시오가피를 장기 복용하였을 때 "보중익정, 견근골, 강한 정신력" 작용이 있는 것으로 사용하였으며 다른 약제와 함께 복용시 거풍습, 장근골, 순기화담, 첨정보수 등에 효과가 있고 장기간 복용시 노화를 막는 약제로 사용하여 왔다.In Chinese traditional oriental medicine, long-term use of sagebrush was used as it had the effect of "bojungikjeong, scapula, strong mental power". It has been used as an anti-aging agent when taken for a long time.
뿐만 아니라 식욕을 돋구고, 기력이 강해지며, 기억력이 좋아지므로 흑룡강성 산간지방에서는 자양강장제라고 하여 가시오가피를 술에 담구어 먹는다고 한다. 70년대 초, 흑룡강성의 노인만성 기관지염 방지에 대한 연구 중 가시오가피가 좋다는 것이 밝혀졌다.In addition, it is said to stimulate appetite, increase energy, and improve memory, so it is said to be a nourishing tonic in the mountainous regions of Heilongjiang. In the early 70's, it was found out that hornwort was good during a study on the prevention of chronic bronchitis in the elderly in Heilongjiang Province.
또한 오가피 분말의 경우 식욕을 돋구고, 기력이 강해지며, 기억력이 좋아지는 효과가 있을 것이다In addition, in the case of ginseng powder, it will have the effect of stimulating appetite, increasing energy, and improving memory.
비타민(Vitamin)은 십자화과의 녹황색채소로 '다채'라고도 불리우며, 본 발명의 비타민의 잎은 농녹색으로 두텁고, 맛이 담백하다. 원래는 수확기까지 기다려 포기를 꽉 채워 수확하지만 국내에서는 밀식 생산하여 주로 어린 채소로 수확한다. 중국채소 중 비타민 A의 함유량이 제일 많다. 성채의 경우 비타민 A 함유량은 시금치의 2배이다. 비타민 B, 비타민 C 도 풍부하다. 중국요리에서는 여러 가지 요리에 들어간다. 본 발명의 '비타민 어린잎'은 당업자에게 알려진 공지의 비타민 종 또는 품종이면 제한되지 않으며, 예를 들어 Brassica rapa var. chinensis 일 수 있다. 또한 발아한지 15 내지 30일경에 수확한 것일 수 있다.Vitamin (Vitamin) is a green-yellow vegetable of the cruciferous family, also called 'Dachae', and the leaves of the vitamin of the present invention are dark green, thick, and have a light taste. Originally, it was harvested by waiting until the harvest season to fill the vines, but in Korea, wheat-based production is mainly used for young vegetables. Among Chinese vegetables, the content of vitamin A is the highest. In the case of sage, the vitamin A content is twice that of spinach. It is also rich in B vitamins and vitamin C. In Chinese cuisine, it is used in many dishes. The 'vitamin young leaf' of the present invention is not limited as long as it is a known vitamin species or variety known to those skilled in the art, for example, Brassica rapa var. can be chinensis. In addition, it may be harvested about 15 to 30 days after germination.
<실시예 3> 액상 조성물의 제조 3<Example 3> Preparation of liquid composition 3
상기 실시예 2의 오가피와 비타민 어린잎 첨가 이외에 천마, 하수오와 산양삼의 함량과 동일한 구기자 및 두충 분말을 포함시켜 약재를 제조한 점을 제외하고는 실시예 1과 동일하다.It is the same as in Example 1, except that, in addition to the addition of green leaf and vitamin young leaves of Example 2, the medicinal materials were prepared by including Goji berry and Duchung powder having the same contents as Chunma, Shuo and wild ginseng.
<비교예 1> <Comparative Example 1>
상기 실시예 2의 천마와 하수오를 혼합하고 이들을 분말화시켜 약재를 제조하였다. 상기 분말 약재 100중량부에 생수 50중량부를 첨가하여 반죽하고 여기에 설탕 30중량부를 첨가한 후 과정까지는 동일하고 이후에 발효균의 접종과 배양을 생략하고 생수 200중량부를 추가로 첨가하여 충분히 교반하여 액상 조성물을 제조하였다.A medicinal material was prepared by mixing Chunma and Hsuo of Example 2 and pulverizing them. Add 50 parts by weight of mineral water to 100 parts by weight of the powdered medicinal material, knead it, and after adding 30 parts by weight of sugar, the process is the same. A composition was prepared.
<비교예 2> <Comparative Example 2>
상기 실시예 1에서 약재에 설탕 30중량부를 첨가한 점을 제외하고는 실시예 1과 동일하게 액상 조성물을 제조하였다.A liquid composition was prepared in the same manner as in Example 1, except that 30 parts by weight of sugar was added to the drug in Example 1.
<실험예 1> 천마, 하수오 및 산양삼의 생리활성 조사<Experimental Example 1> Investigation of physiological activity of Chunma, Hsuo and wild ginseng
먼저, 본 발명에 사용한 천마, 하수오 및 산양삼의 생리활성을 조사하기 위하여, 한국생명공학연구원 생물자원센터(KCTC)에서 분양받은 Lactobacillus plantarum(KCTC 3108)과 Lactobacillus acidophillus(KCTC 3140)를 발효균주로 사용하였다.First, in order to investigate the physiological activity of Chunma, Haushu and wild ginseng used in the present invention, Lactobacillus plantarum (KCTC 3108) and Lactobacillus acidophillus (KCTC 3140), which were sold from the Korea Research Institute of Bioscience and Biotechnology (KCTC), were used as fermentation strains. .
<1-1> 액상 조성물의 추출<1-1> Extraction of liquid composition
상기 실시예 1~3 및 비교예 1에서 제조한 액상 조성물을 물과 메탄올을 사용하여 추출하였다. 상기 조성물에 각각 메탄올 1000ml를 첨가하여 상온에서 24시간 동안 추출하였으며, 이를 3회 반복 후 추출액을 감압하에서 농축하여 분말로 조제하였다. 물 추출물의 경우 물 1000ml를 첨가하여 100℃에서 4시간 동안 각각 3회 반복 추출 후, 동일한 조건으로 감압 농축 후 분말로 조제하였다.The liquid compositions prepared in Examples 1 to 3 and Comparative Example 1 were extracted using water and methanol. 1000 ml of methanol was added to the composition, respectively, and extracted for 24 hours at room temperature. After repeating this three times, the extract was concentrated under reduced pressure to prepare a powder. In the case of the water extract, 1000 ml of water was added, and the extraction was repeated three times for 4 hours at 100° C., and concentrated under reduced pressure under the same conditions to prepare a powder.
비교예 1의 발효 전의 약재 추출물과 실시예 1~3의 발효 후의 약재 추출물의 코직산 함량, 총 폴리페놀 함량, tyrosinase 활성, DPPH에 의한 항산화 활성을 다음과 같은 방법으로 측정하였다.The kojic acid content, total polyphenol content, tyrosinase activity, and antioxidant activity by DPPH of the medicinal extract before fermentation of Comparative Example 1 and the medicinal extract after fermentation of Examples 1 to 3 were measured as follows.
<1-2> 총 폴리페놀 함량 측정<1-2> Measurement of total polyphenol content
총 폴리페놀 함량은 분석방법으로 널리 사용되고 있는 Filin-Denis법 (Swain, T. et al., J. Sci. Food Agric., 10, 83-88 (1959))으로 측정하였다. 각 시료 1mg을 증류수 1mL에 녹이고 10배 희석한 희석액 2mL에 2배로 희석한 Folin 시약 2mL을 첨가하고 잘 혼합한 후 3분간 방치한 후 2mL의 10% Na2CO3를 서서히 가하였다. 혼합액을 1시간동안 방치한 후 분광광도계(HITACHI U-2900, Hitachi High-Technologies Co., Kyoto, Japan)를 사용하여 700nm에서 흡광도를 측정하였다. 이때 총 폴리페놀 화합물의 표준곡선은 tannic acid를 이용하여 최종 농도가 5, 25, 50㎍/㎖이 되도록 하여 위와 같은 방법으로 700nm에서 흡광도를 측정하여 작성하였다.The total polyphenol content was measured by the Filin-Denis method (Swain, T. et al., J. Sci. Food Agric., 10, 83-88 (1959)), which is widely used as an analytical method. 1 mg of each sample was dissolved in 1 mL of distilled water, 2 mL of Folin reagent diluted twice was added to 2 mL of a 10-fold diluted solution, mixed well, left for 3 minutes, and then 2 mL of 10% Na 2 CO 3 was slowly added. After allowing the mixture to stand for 1 hour, absorbance was measured at 700 nm using a spectrophotometer (HITACHI U-2900, Hitachi High-Technologies Co., Kyoto, Japan). At this time, the standard curve of the total polyphenol compound was prepared by measuring the absorbance at 700 nm in the same manner as above by using tannic acid to obtain final concentrations of 5, 25, and 50 μg/ml.
폴리페놀 화합물은 식물계에 널리 분포되어 있는 2차 대사산물로서 flavamoid, catechin, tannin 등이 있다. 특히, 페놀성 화합물들은 전자공여능이 있어 항산화 작용을 나타내는 것으로 알려져 있다.Polyphenol compounds are secondary metabolites widely distributed in the plant kingdom, such as flavamoids, catechins, and tannins. In particular, phenolic compounds are known to exhibit antioxidant activity due to their electron-donating ability.
본 발명에 사용한 천마 및 하수오의 약재의 발효 후와 발효전의 항산화 생리활성을 비교하기 위하여 대표적인 총 폴리페놀 성분의 함량을 측정하였다. The content of representative total polyphenol components was measured to compare the antioxidant physiological activities after fermentation and before fermentation of the medicinal herbs of Chunma and Hsuo used in the present invention.
비교예 1의 메탄올 추출물과 물 추출물의 총 폴리페놀 함량은 각각 1.44±0.12, 1.13±0.07%이었고, 실시예 1의 메탄올 추출물과 물 추출물의 총 폴리페놀 함량은 각각 3.98±0.10, 3.34±0.07%로 발효 전에 비하여 약 2~3배 가까이 증가하였으며, 실시예 2의 경우 4.39±0.17, 3.99±0.07%, 실시예 3의 경우 4.46±0.13, 43.31±0.06%로 각각 발효 전에 비하여 3~4배 증가하였다. 총 폴리페놀 함량 측정 모든 실시예에서 모두 메탄올 추출물이 물 추출물보다 더 높은 함량을 보였다.The total polyphenol contents of the methanol extract and the water extract of Comparative Example 1 were 1.44 ± 0.12 and 1.13 ± 0.07%, respectively, and the total polyphenol contents of the methanol extract and the water extract of Example 1 were 3.98 ± 0.10 and 3.34 ± 0.07%, respectively. increased by about 2-3 times compared to before fermentation, and in Example 2 it was 4.39±0.17, 3.99±0.07%, and in Example 3, 4.46±0.13 and 43.31±0.06%, respectively, an increase of 3-4 times compared to before fermentation, respectively. did Measurement of total polyphenol content In all examples, the methanol extract showed a higher content than the water extract.
위와 같이 발효 전에 비해 발효 후의 총 폴리페놀 함량이 증가한 것으로 나타났는데, 이것은 산화성이 낮은 화합물이 항산화성이 높은 물질로 생물전환 되거나 항산화활성과 관련된 화합물이 발효균 배양시 배지 속으로 유출되었기 때문에 증가한 것이라 판단된다. 즉, 천마, 하수오와 산양삼의 페놀성 물질인 p-hydroxybenzyl alcohol, p-hydroxybenzaldehyde, vanillyl alcohol, vanillin 등의 증가로 인해 폴리페놀 함량도 높아진 것으로 판단된다. 페놀성 물질은 식물의 고유한 색을 부여하는 동시에 식품의 맛에 깊이 관여하며, 천연물에서 얻어지는 항산화성 물질은 주로 phenolic compound와 flavonoid 류의 화합물로서 특히, caffeic acid, chlorogenic, gentistic acid 등이 강한 항산화 효과가 있다. 따라서 발효 중 protease, amylase, lipase 등의 효소가 분비하여 페놀성 물질들이 증가하는데 기인한 것으로 판단되며, 발효에 의해 항산화 활성도 증가되리라 예상된다.As above, it was found that the total polyphenol content increased after fermentation compared to before fermentation. do. In other words, it is judged that the polyphenol content was increased due to the increase in the phenolic substances such as p-hydroxybenzyl alcohol, p-hydroxybenzaldehyde, vanillyl alcohol, and vanillin of Chunma, Suo, and Sanyangsam. Phenolic substances give plants a unique color and are deeply involved in the taste of food. Antioxidant substances obtained from natural products are mainly phenolic compounds and flavonoid compounds. In particular, strong antioxidants such as caffeic acid, chlorogenic acid, and gentistic acid It works. Therefore, it is judged that it is due to the increase of phenolic substances due to the secretion of enzymes such as protease, amylase, and lipase during fermentation, and it is expected that the antioxidant activity will also increase by fermentation.
<1-3> DPPH에 의한 항산화 활성 측정<1-3> Measurement of antioxidant activity by DPPH
항산화 활성 측정은 Abe 등의 방법 (Abe, N. et al., Biosci. Biotechnol. Biochem., 62, 661-666 (1998))으로 측정하였다. 에탄올 100 ml에 α,α'-diphenyl-β-picrylhydrazyl(DPPH) 16mg을 녹인 후 증류수 100ml를 혼합하여 Whatman filter paper No.2에 여과시켜 DPPH 반응 용액을 만들었다. 각 건조분말시료 1ml을 취하고, 여기에 DPPH 반응 용액 5ml을 넣어 혼합한 후 냉암소 (25℃)에서 30분간 반응시킨 후 528nm에서 분광광도계(HITACHI U-2900, HitachiHigh-Technologies Co., Kyoto, Japan)로 흡광도를 측정하였다. DPPH를 이용한 항산화 활성은 다음의 공식을 사용하여 시료 첨가구와 무첨가구의 흡광도차를 백분율(%)로 표시하였다.Antioxidant activity was measured by the method of Abe et al. (Abe, N. et al., Biosci. Biotechnol. Biochem., 62, 661-666 (1998)). After dissolving 16 mg of α,α'-diphenyl-β-picrylhydrazyl (DPPH) in 100 ml of ethanol, 100 ml of distilled water was mixed and filtered through Whatman filter paper No. 2 to prepare a DPPH reaction solution. Take 1 ml of each dry powder sample, add 5 ml of the DPPH reaction solution, mix, and then react in a cool and dark place (25°C) for 30 minutes, followed by a spectrophotometer (HITACHI U-2900, Hitachi High-Technologies Co., Kyoto, Japan ) to measure the absorbance. Antioxidant activity using DPPH was expressed as a percentage (%) of the absorbance difference between the sample-added group and the non-additive group using the following formula.
DPPH radical scavenging activity(%) = [1-(sample absorbance)/control absorbance 528nm]× 100DPPH radical scavenging activity (%) = [1-(sample absorbance)/control absorbance 528nm]×100
항산화 기능은 DPPH 라디칼 소거법을 사용하여 측정하였다. DPPH는 비교적 안정한 자유 라디칼로써, ascorbic acid, tocopherol, polyhydroxy 방향족 화합물, 방향족 아민류에 의해 환원되어 짙은 자색이 탈색되는 원리를 이용하여 항산화 활성을 간단히 측정할 수 있는 동시에 식물체의 항산화 활성과도 연관성이 매우 높기 때문에 많이 이용되고 있는 방법이다.The antioxidant function was measured using the DPPH radical scavenging method. DPPH is a relatively stable free radical, and it is possible to simply measure its antioxidant activity by using the principle that dark purple is discolored by reduction by ascorbic acid, tocopherol, polyhydroxy aromatic compounds, and aromatic amines. This method is widely used because it is high.
본 발명에 사용된 약재의 항산화기능은 DPPH 라디칼 소거법으로 측정한 결과, 비교예 1의 메탄올 추출물은 22.4±3.5%, 물 추출물은 20.5±1.5 %로 나타났으며, 실시예 1의 경우 메탄올 추출물은 45.2±2.8%, 물 추출물은 49.6±1.7%, 실시예 2의 경우 메탄올 추출물은 61.8±6.7%, 물 추출물은 53.4±5.2%, 실시예 3의 경우 메탄올 추출물은 62.8±6.6%, 물 추출물은 54.7±5.2%로 모두 메탄올 추출물이 더 높은 항산화 활성을 나타내었다. 따라서, 비교예 1에 비하여 실시예 1~3이 대략 2~3배 증가하였다. 이러한 결과는 총 폴리페놀 함량 측정 결과에서 나타난 바와 같이 총 폴리페놀 함량이 증가함에 따른 것으로 생각된다.As a result of measuring the antioxidant function of the drug used in the present invention by the DPPH radical scavenging method, the methanol extract of Comparative Example 1 was 22.4±3.5% and the water extract was 20.5±1.5%, and in Example 1, the methanol extract was 45.2±2.8%, water extract 49.6±1.7%, in Example 2, methanol extract 61.8±6.7%, water extract 53.4±5.2%, in Example 3, methanol extract 62.8±6.6%, water extract All methanol extracts showed higher antioxidant activity at 54.7±5.2%. Accordingly, Examples 1 to 3 increased approximately 2-3 times as compared to Comparative Example 1. This result is considered to be due to an increase in the total polyphenol content as shown in the total polyphenol content measurement result.
라디칼 소거 작용은 인체의 질병과 노화를 억제시키는데 중요한 역할을 한다고 알려져 있으며, DPPH 라디칼 소거활성 효과는 페놀성 화합물에 의한 항산화 작용이며, 이러한 물질의 환원력이 클수록 DPPH 라디칼 소거활성이 크다고 보고되었다. 본 발명은 역시 총 폴리페놀 함량이 높게 나온 천마와 하수오의 발효물이 DPPH 라디칼 소거활성이 높게 나타낸 것으로 보아 페놀성 화합물과 DPPH 라디칼 소거능과의 상관관계가 있는 것으로 여겨지며, DPPH 라디탈 소거에 의한 전자공여능이 페놀성 물질에 기인하여 항산화 활성을 나타내는 것으로 사료된다.It is known that radical scavenging activity plays an important role in inhibiting diseases and aging of the human body, and the DPPH radical scavenging activity is an antioxidant activity by a phenolic compound. In the present invention, it is considered that there is a correlation between the phenolic compound and DPPH radical scavenging ability, as the fermented products of Chunma and Hawthorn with high total polyphenol content showed high DPPH radical scavenging activity, and electrons by DPPH radical scavenging It is considered that the donor ability exhibits antioxidant activity due to the phenolic substance.
<1-4> ABTS 라디칼 소거능 측정<1-4> Measurement of ABTS radical scavenging ability
ABTS 라디칼 소거능의 측정은 Re 등(1999, Free Radic. Biol. Med. 26:1231-1237)의 방법에 의해 측정하였다. 7 mM ABTS 600 μL와 7.35 mM K2S2O8 300 μL을 혼합시킨 후 암소에서 14시간 동안 반응시킨 뒤 80 mL 증류수와 희석시킨 다음 734 nm에서 대조구의 흡광도 값이 0.7 ± 0.02가 되도록 조절한 ABTS solution을 사용하였다. 0.05~10 mg/mL의 농도로 맞춘 시료용액 20 μL와 ABTS solution 2 mL를 6분 동안 반응시킨 다음 734nm에서 흡광도를 측정하여 다음과 같은 식에 의해 저해율을 계산하였다.ABTS radical scavenging ability was measured by the method of Re et al. (1999, Free Radic. Biol. Med. 26:1231-1237). After mixing 600 μL of 7 mM ABTS and 300 μL of 7.35 mM K 2 S 2 O 8 , incubated in the dark for 14 hours, diluted with 80 mL of distilled water, and adjusted so that the absorbance value of the control at 734 nm was 0.7 ± 0.02. ABTS solution was used. After reacting with 20 μL of the sample solution adjusted to a concentration of 0.05-10 mg/mL and 2 mL of ABTS solution for 6 minutes, absorbance was measured at 734 nm to calculate the inhibition rate by the following formula.
ABTS 라디칼 소거능(%) = (1 - ) × 100ABTS radical scavenging ability (%) = (1 - ) × 100
비교예 1의 비발효 추출물보다 실시예 1~3의 발효 추출물이 높은 활성능을 나타내었다. 비발효 추출물이 17.20%의 소거율을 나타내었고 발효 추출물은 실시예 1~3서 각각 39.96, 43.61, 47.39%로 다소 차이가 있으나, 비교예 1보다 높았다. DPPH는 자유라디칼을 ABTS는 양이온 라디칼을 소거하는 점에서 서로 차이가 나며 두 기질과 반응물과의 결합정도가 달라지므로 라디칼 제거 능력에서도 차이가 있다고 판단된다.The fermented extracts of Examples 1 to 3 showed higher activity than the non-fermented extracts of Comparative Example 1. The non-fermented extract exhibited an elimination rate of 17.20%, and the fermented extract was 39.96, 43.61, and 47.39% in Examples 1 to 3, respectively, although there was a slight difference, but was higher than that of Comparative Example 1. DPPH is different from each other in that it scavenges free radicals and ABTS scavenges cationic radicals, and the degree of bonding between the two substrates and reactants is different.
<1-5> Superoxide 라디칼 소거능 측정<1-5> Superoxide radical scavenging ability measurement
Superoxide 라디칼 소거능의 측정은 Fontana 등(2001, Biochem. Pharmacol. 61:1253-1257)의 방법을 참고하여 측정하였다. Phosphate buffer(pH 7.4) 0.4 mL에 시료 0.4 mL, NADH 365 μM 0.4 mL, NBT 250 μM 0.4 mL, PMS 75 μM 0.4 mL를 첨가 후 실온에서 5분 동안 반응시킨 다음 562 nm에서 흡광도를 측정하여 다음과 같은 식에 의해 저해율을 계산하였다.Superoxide radical scavenging ability was measured with reference to the method of Fontana et al. (2001, Biochem. Pharmacol. 61:1253-1257). After adding 0.4 mL of sample, 0.4 mL of NADH 365 μM, 0.4 mL of NBT 250 μM, and 0.4 mL of PMS 75 μM to 0.4 mL of phosphate buffer (pH 7.4), react at room temperature for 5 minutes, and then measure the absorbance at 562 nm to obtain the following The inhibition rate was calculated by the same formula.
Superoxide 라디칼 소거능(%) = (1 - ) × 100Superoxide radical scavenging ability (%) = (1 - ) × 100
비교예 1의 비발효 추출물이 1.9% 억제효과를 나타내었고 실시예 1~3의 발효 추출물은 각각 33.13, 36.06, 36.17%로 높은 활성능을 보였다. 이는 발효 추출물의 활성능이 높은 것을 확인할 수 있었다. 산화물은 체내에서 산화스트레스를 유발하는 것으로 알려져 있으며 노화의 대표적 원인이라 할 수 있다. 산화물 중 활성산소는 인체에 매우 독성이 강한 물질로써 생성과 동시에 superoxide의 저해물질인 superoxide dismutase(SOD)에 의해서 독성이 사라지는 것으로 알려져 있다. 따라서 천마와 하수오 분말을 이용한 발효에 의해 생성된 활성물질들에 의해 superoxide 라디칼 소거능이 증가한 것으로 판단된다.The non-fermented extract of Comparative Example 1 showed a 1.9% inhibitory effect, and the fermented extracts of Examples 1 to 3 showed high activity at 33.13, 36.06, and 36.17%, respectively. It was confirmed that the activity of the ferment extract was high. Oxides are known to cause oxidative stress in the body and can be said to be a representative cause of aging. Among the oxides, active oxygen is very toxic to the human body, and it is known that the toxicity disappears by superoxide dismutase (SOD), an inhibitor of superoxide at the same time as it is created. Therefore, it is judged that the superoxide radical scavenging ability is increased by the active substances produced by fermentation using Chunma and Hawthorn powder.
발효균 균사체를 발효시킨 천마와 하수오 약재에 대하여 발효균 균사체는 발효 배양 기간 동안 전반적으로 양호한 균사체 성장을 나타내었으며, 총 폴리페놀 및 DPPH radical 소거법, ABTS 라디칼 소거능, Superoxide 라디칼 소거능에 의한 항산화 기능은 발효전보다 크게 증가하였으며, 메탄올 추출물에서 보다 높게 나타났다. For the fermented Chunma and Hasuo medicinals, the fermented mycelium showed overall good mycelial growth during the fermentation culture period. increased, and was higher in the methanol extract.
<실험예 2> 발효과정에서 ginsenoside의 함량변화<Experimental Example 2> Change in the content of ginsenoside during fermentation
천마, 하수오 및 산양삼 분말에 대한 유산균 균주에 의한 발효시에 다양한 ginsenoside의 함량 변화를 조사하였다.Changes in the contents of various ginsenosides were investigated during fermentation by lactic acid bacteria strains for Chunma, Hasuo and wild ginseng powder.
먼저, 발효과정에서 ginsenoside Rb1의 함량분석을 실시한 결과 실시예 1의 약재는 3.15 ㎎/g에서 발효 10시간 후 2.19 ㎎/g으로, 20시간 후는 2.05 ㎎/g, 30시간 후에는 2.01 ㎎/g, 그리고 40시간 후에는 0.45 ㎎/g을 나타내었다. 발효과정에서 ginsenoside Rb2의 함량 분석을 실시한 결과, 실시예 1의 약재는 2.37 ㎎/g에서 발효 10시간 후 1.60 ㎎/g으로, 20시간 후는 1.59 ㎎/g, 30시간 후에는 1.49 ㎎/g, 그리고, 40시간 후에는 0.37 ㎎/g을 나타내었다. 발효과정에서 ginsenoside Rc의 함량 분석을 실시한 결과, 실시예 1의 약재는 1.98 ㎎/g에서 발효 10시간 후 1.60 ㎎/g으로, 20시간 후는 1.54 ㎎/g, 30시간 후에는 1.35 ㎎/g, 그리고 40시간 후에는 0.22 ㎎/g을 나타내었다. 발효과정에서 ginsenoside Rd의 함량 분석을 실시한 결과, 실시예 1의 약재는 0.93 ㎎/g에서 발효 10시간 후 0.91 ㎎/g으로, 20시간 후 0.90 ㎎/g, 30시간 후에는 0.86 ㎎/g, 그리고 40시간 후에는 0.36 ㎎/g을 나타내었는다. 이들 ginsenoside들은 모두 초기에는 감소하는 경향을 나타내다가 발효 말미에 급격한 감소를 나타내었다. 기타 ginsenoside Re, ginsenoside Rf, ginsenoside Rh1는 그 함량 변화가 크지 않았다.First, as a result of analyzing the content of ginsenoside Rb1 in the fermentation process, the drug of Example 1 was 3.15 mg/g to 2.19 mg/g after 10 hours of fermentation, 2.05 mg/g after 20 hours, 2.01 mg/g after 30 hours g, and 0.45 mg/g after 40 hours. As a result of analyzing the content of ginsenoside Rb2 in the fermentation process, the drug of Example 1 was from 2.37 mg/g to 1.60 mg/g after 10 hours of fermentation, 1.59 mg/g after 20 hours, and 1.49 mg/g after 30 hours. , and 0.37 mg/g after 40 hours. As a result of analyzing the content of ginsenoside Rc in the fermentation process, the drug of Example 1 was 1.98 mg/g to 1.60 mg/g after 10 hours of fermentation, 1.54 mg/g after 20 hours, and 1.35 mg/g after 30 hours. , and 0.22 mg/g after 40 hours. As a result of analyzing the content of ginsenoside Rd in the fermentation process, the drug of Example 1 was 0.93 mg/g to 0.91 mg/g after 10 hours of fermentation, 0.90 mg/g after 20 hours, 0.86 mg/g after 30 hours, And after 40 hours, it showed 0.36 mg/g. All of these ginsenosides showed a tendency to decrease at the beginning, but then showed a sharp decrease at the end of fermentation. The content of other ginsenoside Re, ginsenoside Rf, and ginsenoside Rh1 was not significantly changed.
발효과정에서 ginsenoside Rg1의 함량분석을 실시한 결과 실시예 1의 약재는0.38 ㎎/g에서 발효 10시간 후 0.217 ㎎/g으로, 20시간 후는 0.26 ㎎/g, 30시간후에는 0.25 ㎎/g, 그리고 40시간 후에는 0.00 ㎎/g을 나타내어 발효 말미에 급격한 감소를 나타내어 분해과정에 의해 완전히 분해됨을 알 수 있었다.As a result of analyzing the content of ginsenoside Rg1 in the fermentation process, the drug of Example 1 was 0.38 mg/g to 0.217 mg/g after 10 hours of fermentation, 0.26 mg/g after 20 hours, 0.25 mg/g after 30 hours, And after 40 hours, it showed 0.00 mg/g, which showed a sharp decrease at the end of fermentation, indicating that it was completely decomposed by the decomposition process.
발효과정에서 ginsenoside Rg3의 함량분석을 실시한 결과 실시예 1의 약재는 0.12 ㎎/g에서 발효 10시간 후 0.16 ㎎/g으로, 20시간 후는 0..18 ㎎/g, 30시간후에는 0.20 ㎎/g, 그리고 40시간 후에는 0.31 ㎎/g을 나타내어 발효 말미에 급격한 함량의 증가를 나타내었다.As a result of analyzing the content of ginsenoside Rg3 in the fermentation process, the drug of Example 1 was 0.12 mg/g to 0.16 mg/g after 10 hours of fermentation, 0.18 mg/g after 20 hours, and 0.20 mg after 30 hours /g, and 0.31 mg/g after 40 hours, indicating a sharp increase in the content at the end of fermentation.
<실험예 3> 관능실험<Experimental Example 3> Sensory experiment
관능검사는 혼탁도, 잡냄새, 기호도로 구분하여 9 점 평정법을 이용하여 평가하였다. 연령과 성별을 고려하여 10 대 ~ 40 대 성인 남녀를 각각 연령대별로 10 명씩 총 40 명을 선발하였다. 그 결과를 하기 표 1에 기재하였다.The sensory test was evaluated using a 9-point rating method for turbidity, odor, and preference. In consideration of age and gender, a total of 40 males and females in their teens and 40s were selected, 10 for each age group. The results are shown in Table 1 below.
* 관능 검사 수치(9 : 아주 좋음, 5 : 보통임 0 : 아주 나쁨)* Sensory test value (9: very good, 5: moderate, 0: very poor)
상기 표 1의 결과로 볼 때, 실시예 1~3은 약재와 설탕을 적절한 중량비로 발효액을 제조하였기 때문에 혼탁도와 낮으며, 잡냄새가 거의 나지 않아 기호도가 높음을 알 수 있었다.From the results of Table 1, it can be seen that Examples 1 to 3 had low turbidity and low turbidity because the fermented broth was prepared in an appropriate weight ratio of herbs and sugar, and had a high degree of preference due to almost no odor.
반면, 비교예 2의 경우에는 설탕을 포함하지 않고 발효액을 제조하였기 때문에 발효가 충분히 일어나지 않아 혼탁도가 높고, 잡냄새가 많이 나서 기호도가 현저히 떨어짐을 알 수 있었다.On the other hand, in the case of Comparative Example 2, since the fermentation broth was prepared without sugar, it was found that the fermentation did not occur sufficiently, so that the turbidity was high, and the preference was significantly lowered due to a lot of miscellaneous smell.
이상, 본 발명의 바람직한 실시예를 들어 상세하게 본 발명은 상기 실시예에 한정되는 것은 아니며, 본 발명의 기술적 사상의 범위 내에서 당 분야에서 통상의 지식을 가진 자에 의하여 여러 가지 변형이 가능하다.As mentioned above, the present invention is not limited to the above embodiments in detail by giving preferred embodiments of the present invention, and various modifications are possible by those of ordinary skill in the art within the scope of the technical spirit of the present invention. .
Claims (6)
2) 하수오와 산양삼을 찌고 말리는 증폭 과정을 2~4회 수행 반복하는 단계;
3) 상기 1) 천마 및 2) 하수오와 산양삼을 혼합하고 상기 약재를 분말화하고, 구기자, 두충, 울금, 둥굴레, 말토덱스트린, 현미, 보리, 검정콩, 들깨 및 검정깨로 이루어진 군중에서 선택된 1종 이상의 추가적 성분의 분말을 혼합하는 단계;
4) 상기 천마: 하수오 : 산양삼의 함량은 1: 0.5~2 : 0.5~2의 중량비의 분말 약재에 건조하고 분쇄된 오가피 및 비타민 어린잎을 혼합하는 단계;
5) 상기 분말을 생수로 반죽하고 설탕을 첨가하여 배양액을 제조하는 단계;
6) 상기 배양액을 30~35℃에서 1~3일 동안 배양된 락토바실러스 플란타룸(Lactobacillus plantarum) KCTC 3108 및 락토바실러스 애시도필러스(Lactobacillus acidophillus) KCTC 3140 유산균 발효균주로 발효시키는 단계; 및
7) 상기 발효물을 여과하고 농축하여 55°Brix의 액상 제품을 제조하는 단계;를 포함하는 기능성 액상 건강식품의 제조 방법.1) Repeating the amplification process of slicing, steaming, and drying Chunma 2 to 4 times, followed by drying;
2) repeating the amplification process of steaming and drying ginseng and wild ginseng 2 to 4 times;
3) Mix 1) Cheonma and 2) Sauerkraut and wild ginseng, and powder the above medicine, and one selected from the group consisting of Goji berry, Duchung, Turmeric, Dungulle, Maltodextrin, Brown rice, Barley, Black soybean, Perilla and Black sesame. mixing the powders of the above additional ingredients;
4) The Chunma: Hsuo: The content of wild ginseng is 1: 0.5-2: mixing the dried and pulverized sagebrush and vitamin young leaves with the powdered medicine in a weight ratio of 0.5-2;
5) kneading the powder with mineral water and adding sugar to prepare a culture solution;
6) fermenting the culture solution with Lactobacillus plantarum KCTC 3108 and Lactobacillus acidophillus KCTC 3140 lactic acid bacteria fermented strains cultured for 1 to 3 days at 30-35° C.; and
7) manufacturing a liquid product of 55 ° Brix by filtering and concentrating the fermented product; manufacturing method of a functional liquid health food comprising.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190169219A KR102365198B1 (en) | 2019-12-17 | 2019-12-17 | Facturing method of functional liquefied healthfoods using Gastroia elata Blume, Polygonum multiflorum Thunberg and mountain ginseng |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190169219A KR102365198B1 (en) | 2019-12-17 | 2019-12-17 | Facturing method of functional liquefied healthfoods using Gastroia elata Blume, Polygonum multiflorum Thunberg and mountain ginseng |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210077509A KR20210077509A (en) | 2021-06-25 |
KR102365198B1 true KR102365198B1 (en) | 2022-02-21 |
Family
ID=76629294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190169219A KR102365198B1 (en) | 2019-12-17 | 2019-12-17 | Facturing method of functional liquefied healthfoods using Gastroia elata Blume, Polygonum multiflorum Thunberg and mountain ginseng |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102365198B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101055746B1 (en) * | 2010-10-10 | 2011-08-11 | 재단법인 진안홍삼연구소 | A pharmaceutical comprising the extract of red panax ginseng, gastrodia rhizoma and polygoni multiflori radix for treating or preventing hyperlipidemia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150082760A (en) * | 2014-01-08 | 2015-07-16 | 주식회사 풀무원 | Fermented composition for fatigue recovery comprising baby leaves of the vitamin with antioxidant activity |
KR101696193B1 (en) * | 2015-04-14 | 2017-01-13 | 대전대학교 산학협력단 | Composition comprising steamed and fermented Gastrodiae rhizoma extract with increased anti-inflammatory or antioxidant activity and preparation method thereof |
-
2019
- 2019-12-17 KR KR1020190169219A patent/KR102365198B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101055746B1 (en) * | 2010-10-10 | 2011-08-11 | 재단법인 진안홍삼연구소 | A pharmaceutical comprising the extract of red panax ginseng, gastrodia rhizoma and polygoni multiflori radix for treating or preventing hyperlipidemia |
Also Published As
Publication number | Publication date |
---|---|
KR20210077509A (en) | 2021-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8637098B2 (en) | Natural plant extract composition for prevention and recovery of hyperlipidemia and stroke, natural tea containing the same as active ingredient and method for preparing the natural tea | |
KR102136052B1 (en) | Composition for Liver Protection Containing Hub Extract and Beverage Thereof | |
KR20120014712A (en) | Drink composition comprising the extracts of momordica charantia and manufacturing method thereof | |
KR101467837B1 (en) | Manufacturing method of fermented red ginseng extract with enhanced ginsenosides Rg3 and antioxidant activity | |
KR101914344B1 (en) | A moisturizing and anti-wrinkle cosmetic composition comprising fermented barley, fermented pear juice, fermented soybeans and fermented pomegranate extract and the method preparation of thereof | |
Chen et al. | Traditional food, modern food and nutritional value of Sea buckthorn (Hippophae rhamnoides L.): A review | |
KR102387371B1 (en) | Fermented Stauntonia hexaphylla with improved antioxidant activity and uses thereof | |
KR20030026939A (en) | The effective tea compositions with guava leaf as chief element for remedy against diabetes, obesity and aging, and functional foods | |
KR102298700B1 (en) | Facturing method of functional liquefied healthfoods using Gastroia elata Blume and Polygonum multiflorum Thunberg | |
KR101253658B1 (en) | Manufacturing method of treated puffing and fermentation red ginseng concentrate | |
KR102012872B1 (en) | High concentrate for beverage containing black raspberry, plantaginis asiatica l., schizandra chinensis, lycii fructus and torilis japonica decandolle and the high concentrate for beverage prepared from the same | |
KR102176938B1 (en) | Cosmetic Composition Comprising Fermented Liquor of Natural Plant and Preparation Methods Thereof | |
KR102225182B1 (en) | Freeze-dryed Makkoli and preparation method of the same | |
KR101024238B1 (en) | The manufacturing method of vinegar using mainly Gastrodia elata Blume, and its product | |
KR102168192B1 (en) | Healthful mixed tea development using fermented herbs, fruits and shiitake | |
Ma et al. | Nutritional value and processing technology of mulberry fruit products | |
KR101962766B1 (en) | Improving method for bitter taste of bitter gourd liquid tea and preparing method for bitter taste improved bitter gourd liquid tea using the same | |
KR102365198B1 (en) | Facturing method of functional liquefied healthfoods using Gastroia elata Blume, Polygonum multiflorum Thunberg and mountain ginseng | |
KR102132537B1 (en) | Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof | |
KR102136053B1 (en) | Composition for Removing Hangover Comprising Herb Extract and Beverage Thereof | |
KR101811227B1 (en) | Composition for Immune Enhancement, Fatigue Recovery, Physiologically Active, Detoxification Comprising Extracts of Lycium chinence miller, Rubus coreanus Miq. & Schisandra chinensis | |
KR20170014238A (en) | Fermented black garlic comprising kochujang and Preparation Method Thereof | |
KR20200142768A (en) | Composition for hangover cure conprising oriental herbal extract | |
KR102211759B1 (en) | Health-promoting sphere comprising cacao nibs and preparation method thereof | |
KR102444816B1 (en) | Preparing method of the functional rice paste using mulberry leaves, mulberry and glutinous rice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |